Conference Reports for NATAP

Back

18th CROI Conference on Retroviruses and Opportunistic Infections Boston, MA Feb 27 - March 2, 2011     Inflammation and Intervention: how does HIV cause AIDS and how does it cause disease despite ART - David Margolis, MD University of North Carolina - (04/11/11)   Bone and Vitamin D at CROI 2011 -  By Todd T. Brown, MD, PhD - (03/26/11)   CROI 2011 Immunology Report - written by David Margolis, MD, University of North Carolina (03/22/11)   Summary from CROI for Hepatitis Coinfection - New drugs for treatment of hepatitis C are becoming available: what does that mean for the HIV coinfected patient? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/19/11)   Integrating Integrase Inhibitors and other antiretroviral stories - Joe Eron MD Professor of Medicine; UNC Chapel Hill - (03/15/11)   Clinical Pharmacology at CROI 2011 (HIV & HCV) - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center (03/14/11)   Update on the "cure" and metabolic complications written by Pablo Tebas MD University of Pennsylvania (03/13/11)   Chronic Inflammation and HIV: CROI 2011 - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine (03/11/11)   CROI 2011 Report - Selected Topics - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine - (03/8/11)   The Kidney at CROI - Christina M. Wyatt, MD Assistant Professor, Medicine Nephrology Mount Sinai School of Medicine New York, NY - (03/8/11)   HIV Prevention at CROI 2011 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/8/11)   Vitamin D3 Supplementation Decreases Parathyroid Hormone (PTH) in HIV-Infected Youth Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: Randomized, Double-blind, Placebo-controlled Multicenter Trial Adolescent Trials Network (ATN) study 063 - (03/29/11)   No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis - (03/29/11)   Risk of Fractures Associated with HIV/Hepatitis C Coinfection - (03/28/11)   Changes in Body Composition after Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir in Virologically Suppressed HIV-1-Infected Patients (SPIRAL-LIP substudy) - (03/26/11)   Bone & HIV CROI 2011 - (03/26/11)   COMPREHENSIVE LIPID EVALUATION IN PATIENTS SWITCHING FROM RITONAVIR BOOSTED PROTEASE INHIBITOR (PI/r)-BASED TO RALTEGRAVIR-BASED ANTIRETROVIRAL THERAPY: THE SPIRAL-met SUBSTUDY - (03/26/11)   Antiretroviral CNS Penetration-Effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma - (03/24/11)   Early HAART in TB-Treated Patients Recommended in 2 Studies at CROI for Patients with <50 CD4s - (03/24/11)   Turnover Following Viral Control Correlates with Markers of Microbial Translocation in Treatment-Naïve Patients Receiving Raltegravir (RAL)- based Antiretroviral Therapy (ART): Preliminary Results from ACTG A5248 - (03/24/11)   CD4 Nadir Drives Persistence of Monocytes and T Lymphocytes Activation in Virologically Suppressed HIV-infected Patients - (03/24/11)   Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART - (03/24/11)   Bone Loss in HIV-Negatives in PrEP Study: 'a surprising percent of HIV-neg MSM had low bone mineral density before starting TDF, drug use associated with bone mineral density loss - vitamin D/calcium supplementation was protective'; in some HIV+ persons low BMD likely predated HIV-infection....in summary Kathy Mulligan said "it is not known whether there will be any long-term clinically important effects of PrEP with TDF/3TC (Truvada) on bone health" - (03/23/11)   BMD Loss in HIV TDF PrEP - 2 studies - (03/22/11)   Advances in PrEP - (03/22/11)   Adding Maraviroc Does Not Boost CD4s or Quiet T-Cell Activation - written by Mark Mascolini - (03/22/11)   Risk of Stage 1 AIDS Dementia 12% Over 2 Years in Asymptomatic People - written by Mark Mascolini - (03/22/11)   Sustained Response to Anti-HCV Therapy Higher During Acute Infection in HIV Positives - written by Mark Mascolini - (03/22/11)   Boceprevir Boosts Sustained Virologic Response Rate With HCV Genotype 1 - written by Mark Mascolini - (03/22/11)   Boceprevir Improves SVR With PegIFN/RBV After Failure or Relapse With HCV-1 - written by Mark Mascolini - (03/22/11)   US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/21/11)   HIV Affects Brain Immediately After Infection with HIV RNA in the CSF & Inflammation & Brain Injury Continues Unfolding During Chronic Infection & There is a Need for Routine Monitoring - (03/21/11)   Lowest CD4 Count Below 200, by Itself, Raises Heart Disease Risk With HIV: HIV Is a Risk Factor for Heart Disease - (03/21/11)   HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors - (03/21/11)   High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam - (03/21/11)   Therapeutic Darunavir and Etravirine Concentrations in Cerebrospinal Fluid - (03/21/11)   Early Clearance of HCV RNA in HCV Genotype 1 Treatment-naïve Patients Treated with Telaprevir, Peginterferon and Ribavirin: Pooled Analysis of the Phase 3 Trials ADVANCE and ILLUMINATE - (03/21/11)   Trunk and Visceral Fat Gains With Atazanavir & Efavirenz in ACTG A5224s - written by Mark Mascolini - (03/20/11)   Vitamin D Supplements May Limit Tenofovir Bone Toxicity - written by Mark Mascolini - (03/20/11)   Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members - (03/19/11)   Comprehensive Lipid Evaluation in Patients Switching from PI/r-based cART to a RAL-based cART: The SPIRAL Substudy - (03/19/11)   US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/19/11)   On-Treatment Viral Loads Fell Steadily Since 1997 in Large US-Canadian Analysis: diaparities for Blacks & IDUs - written by Mark Mascolini - (03/19/11)   Minocycline Does Not Improve HIV-Associated Neurocognitive Disorder - written by Mark Mascolini - (03/19/11)   Early Brain Injury Visualized in People With Recent HIV Infection - written by Mark Mascolini - (03/19/11)   Results from a Single Arm Study of Darunavir/RitonavirPlus Raltegravir in Treatment-Naïve HIV-1-Infected Patients (ACTG A5262) - (03/17/11)   First-Line Darunavir/Raltegravir Riskier With Viral Load Above 100,000 - written by Mark Mascolini - (03/17/11)   Carotid Atherosclerosis Is Related to HIV Duration and Anti-inflammatory Profile and Not to ARV Exposure: The CHIC Controlled Study - (03/17/11)   D-dimer Levels Correlate with Inflammatory and Endothelial Activation Markers in HIV-infected Adults - (03/17/11)   (NIH Study) Circulating Markers of Endothelial Dysfunction, Coagulation and Tissue Fibrosis Prior to Incident Venous Thromboembolism in Patients with HIV Infection - (03/17/11)   Kinetics of Platelet Counts following Interruption of ART: Results from the SMART Study (coagulation pathways, HIV replication itself or inflammation) - (03/17/11)   Switch and Stop Rates 25% and 12% in First ART Year in 18-Cohort Study - written by Mark Mascolini - (03/17/11)   ATN 083: Longitudinal Changes in Cardiovascular Risk Markers among HIV Infected and at Risk Adolescents: "Endothelial dysfunction as measured by sVCAM-1 is higher in HIV+ adolescents than HIV- individuals" - (03/16/11)   Endothelial Dysfunction More Common in HIV-Positive Than Negative Adolescents - written by Mark Mascolini - (03/16/11)   Mortality With Acute Coronary Syndrome Higher in People With HIV - written by Mark Mascolini - (03/14/11)   Coronary Artery Plaque Linked to Low Fat in MACS Men With HIV - written by Mark Mascolini - (03/14/11)   The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/15/11)   Low CD4 Count on Effective HAART is Associated With Immunologic and Vascular Dysfunction - (03/15/11)   Viral Load (But Not Antiretrovirals) and HCV Tied to 10-Year Fracture Risk: fracture risk higher in HIV+ vs HIV-neg - written by Mark Mascolini - (03/14/11)   Survival After Cancer Diagnosis Improves in US HIV Cohort: 'Incidence (new diagnoses) of AIDS cancers dropped, as did incidence of non-AIDS infection-related cancers. But incidence of non-AIDS cancers not related to infection rose since the arrival of triple antiretroviral therapy' - written by Mark Mascolini - (03/14/11)   Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/r) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/r) help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy (ART) initiation (03/14/11)   Firstline HAART Causes Bone Loss (03/14/11)   Glycated Hemoglobin A1C as Screening for Diabetes Mellitus in HIV Infected Individuals (03/13/11)   LOW BONE MASS IN BEHAVIORALLY HIV-INFECTED YOUNG MEN ON ANTIRETROVIRAL THERAPY: Adolescent Trials Network (ATN) Protocol 021B (03/13/11)   HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS (03/13/11)   Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation (03/13/11)   Recombinant Interleukin-7 (CYT107) Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-Infected Immunological Non-Responder Patients (03/13/11)   Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks (03/12/11)   Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 datafrom the randomized, double-blind, Phase III ECHO and THRIVE trials (03/12/11)   Bone Effects of Rosiglitazone in HIV-Infected Patients with Lipoatrophy (03/11/11)   Recombinant IL-7 Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-infected Immunological Non-responder Patients (03/11/11)   Nutritional Intervention with NR100157 Restores Gut Microbiota in HIV-1-infected Adults Not on HAART and Reduces Systemic Immune Activation (03/10/11)   Prompt, Significant Reduction of Activation and Proliferation Markers in CD4+ and CD8+ T Cell Subsets despite Incomplete Viral Suppression: Proof-of-Concept for AV-HALT-A New Class of Anti-HIV Therapeutics Inhibiting Both HIV Replication and Immune Activation (03/10/11)   Immunomodulatory Effects of Hydroxychloroquine in HIV-Infected ART-Treated Immunological Non Responders: 'reduces inflammation & activation' (03/10/11)   HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors (03/10/11)   Diabetes Mellitus in Treated HIV-Infected Patients: Incidence over Ten Years in 1,046 patients from the ANRS CO8 APROCO-COPILOTE Cohort (03/10/11)   Invasive Anal Cancer Seen With Relatively High CD4s and Low HIV Loads - written by Mark Mascolini - (03/9/11)   Statins May Lower Risk of non-Hodgkin Lymphoma in People With HIV - written by Mark Mascolini - (03/9/11)   Earlier Occurrence of the Frailty Phenotype in HIV-1-infected Men than in HIV-uninfected Men in the Multicenter AIDS Cohort Study (MACS) - (03/9/11)   Prevalence and Prognostic Factors of Chronic Kidney Disease in HIV-infected Patients, HIV-NAT 006 Cohort, Thailand: "high prevalence of advanced chronic kidney disease...more diabetes/hypertension" - pdf attached - (03/9/11)   Aging and Non-HIV-associated Co-morbidity in HIV+ Persons: The SHCS - pdf attached - (03/9/11)   Microbial Translocation (MT)-induced Immune Activation Associates to Atherosclerosis in cART treated HIV pos Patients - (03/9/11)   Immunologic Failure Despite Suppressive ART Is Related to Increased Inflammation and Evidence of Microbial Translocation and Inflammation & Activation Persist Even Despite Immune Success - (03/9/11)   Renal Insufficiency among HIV-infected, ART-naïve Individuals in Lilongwe, Malawi: Implications for Tenofovir use in antiretroviral treatment and prevention of mother to child transmission programs. - (03/9/11)   Earlier Occurrence of the Frailty Phenotype in HIV+ Men than in HIV- Men: The MACS - (03/9/11)   Renal Insufficiency, Nephrotoxicity, and Mortality among HIV-infected Adults on TDF in a South African Cohort: A Marginal Structural Models Analysis - pdf attached - (03/9/11)   Cystain C - 'Lipid Particle Concentrations and Markers of Renal Disease: SMART' - Unfavorable lipoprotein levels were associated with elevated cystatin C levels, but not with impaired eGFR. Cystatin C may better detect earlier reductions in kidney function - (03/9/11)   Changing Patterns of Causes of Death in the Swiss HIV Cohort Study (SHCS) 2005-2009 - (03/9/11)   QDMRK, A Phase III Study of the Safety & Efficacy of Once Daily (QD) Versus Twice Daily (BID) Raltegravir (RAL) in Combination Therapy for Treatment-Naïve HIV-Infected Patients (Pts) - (03/9/11)   Telapravir Promotes Early Clearance of HCV RNA With PEG-IFN/RBV, Early Response Predicts Outcome (weeks 1,2,4) - written by Mark Mascolini - (03/8/11)   Fibrosis Predicts Renal Trouble With Tenofovir in HIV/HBV-Coinfected - written by Mark Mascolini - (03/8/11)   Liver Death Rate Twice Higher With HBV Than HCV in Gay HIV+ Men of MACS - written by Mark Mascolini - (03/8/11)   HIV, Black Race, and Multiple Partners Raise Risk of Repeat Syphilis in California Gays - written by Mark Mascolini - (03/8/11)   CD4 Decline Before ART Faster in More Recent Years in ATHENA Cohort: "may have implications for planning on when to start cART." - written by Mark Mascolini - (03/8/11)   Steady-state pharmacokinetic parameters of nevirapine extended release formulation tablets in children with HIV-1 infection: an open-label, multiple-dose, cross-over study - (03/7/11)   Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years of Treatment (Tx): 156 Week (Wk) Results from STARTMRK - (03/7/11)   Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial - (03/7/11)   The Effect of Bimonthly Supplementation with Oral Cholecalciferol and Calcium on 2 Year Bone Mass Accrual in HIV-infected Children and Adolescents - (03/7/11)   Renal Impairment in Patients Receiving a TDF-based cART Regimen: Impact of TDF Concentration? - (03/7/11)   Central Fat Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Substudy of ACTG A5202 - (03/7/11)   Decreased Limb Muscle and Increased Central Adiposity Are Associated with 5-Year All-cause Mortality in HIV Infection - (03/7/11)   Predictors of Chronic Kidney Disease in the SMART trial - (03/7/11)   Maraviroc 300mg Once Daily + Darunavir/Ritonavir 800/100mg Once Daily Provides Maraviroc Trough Concentrations Comparable to Trough Concentrations in HIV-1 Patients Taking Maraviroc 300mg Twice Daily + Truvada: Implications for Phase 3 Studies - (03/5/11)   Genotypic Analysis of Cellular HIV V3 DNA to Predict Virologic Response to Maraviroc: Performance of Population-based and 454 Deep V3 Sequencing - (03/5/11)   Gut-associated Lymphoid Tissue Fibrosis Is Associated with CD4+ T Cell Activation and Poor HIV-specific CD8+ T cell Responses During Suppressive Antiretroviral Therapy - (03/5/11)   Impaired Endothelial Function Is Associated with Increased Frequencies of CCR5+ and HIV-specific T cells During Treated HIV Infection - (03/5/11)   The Immunomodulatory Effects of Maraviroc Intensification among ART-suppressed Patients with Incomplete CD4 Recovery - (03/5/11)   Antiretroviral Therapy Initiation during Acute/Early HIV Infection vs. Later ART Initiation is Associated with Improved Immunologic and Virologic Parameters during Suppressive ART - (03/5/11)   Predicting maraviroc responses according to number or percentage of X4-using virus among treatment-experienced patients - (03/4/11)   Neuroprotective MVC Monotherapy in SIV-infected Macaques - (03/4/11)   Relative performance of ESTA, Trofile, 454 deep sequencing and "reflex" testing for HIV tropism in the MOTIVATE screening population of therapy experienced patients - (03/4/11)   Interrupted Antiretrovirals Raise Chronic Kidney Disease Risk 50% in SMART - written by Mark Mascolini - (03/4/11)   New Integrase Inhibitor Controls Toughest Raltegravir-Resistant Virus - written by Mark Mascolini - (03/4/11)   Diabetes Incidence in People With HIV Falling Since 1999-2000 in France - written by Mark Mascolini - (03/4/11)   Male-Female and White-Black ART Disparities Persist in US - written by Mark Mascolini - (03/4/11)   Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks - written by Mark Mascolini - (03/4/11)   Post-Menopausal Women Have increased HIV transmission risk and Higher TDF Blood Levels - (03/3/11)   Creating an HIV-resistant Immune System: Using CXCR4 ZFN to Edit the Human Genome - (03/3/11)   Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference - (03/3/11)   Telaprevir + Peginterferon and Ribavirin: phase 2a study in coinfected patients on HAART Reported at CROI March 2 2011 - (03/3/11)   Interim Analysis of Phase 2a Study of Telaprevir + Peginterferon/Ribavirin in HCV/HIV Coinfected Patients - (03/3/11)   GSK1349572 Integrase in Raltegravir Resistant Patients - (03/3/11)   GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects - (03/2/11)   Diabetes and cIMT Linked to Worse Neurocognitive Performance With HIV written by Mark Mascolini - (03/2/11)   Poor CD4 Response Despite Undetectable Load Marked by Vascular and T-Cell Dysfunction written by Mark Mascolini - (03/2/11)   Vitamin D3 Supplements May Thwart Diabetes Emergence in People With HIV written by Mark Mascolini - (03/2/11)   Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks written by Mark Mascolini - (03/2/11)   Duration of PIs or NNRTIs Has No Consistent Impact on Non-AIDS Cancer Rates written by Mark Mascolini - (03/2/11)   Low Limb Muscle, High Visceral Fat Double 5-Year Risk of Death in US Cohort written by Mark Mascolini - (03/2/11)   Vitamin D Boost Does Not Improve Endothelial Function With HIV written by Mark Mascolini - (03/2/11)   FDA Trial Meta-Analysis Does Not See Higher MI Risk With Abacavir written by Mark Mascolini - (03/2/11)   Cancer Risk Remains High for People Who Had AIDS as a Child written by Mark Mascolini - (03/2/11)   Sangamo's Gene Therapy for HIV is Safe, Helps Immune Cells in Early Trial - (03/2/11)   Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions - (03/2/11)   Pharmacokinetic Interactions Between Antiretroviral Agents and the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/2/11)   Lower "Community Viral Load" in SF Linked to Fewer New HIV Cases written by Mark Mascolini - (03/1/11)   Higher Fracture Rate With HIV + HCV Than With Either Virus Alone written by Mark Mascolini - (03/1/11)   Intensification With Raltegravir Has No Impact on Reservoir of Replicating Virus written by Mark Mascolini - (03/1/11)   Viral Load and CD4 Changes With Ritonavir-Boosted and Unboosted Attachment Inhibitor written by Mark Mascolini - (03/1/11)   HIV Duration, Not ART, Tied to Atherosclerosis Marker in Large Case-Control Study written by Mark Mascolini - (03/1/11)   Black Race Tied to Virologic Failure in ACTG Trials--But Blacks Gained More CD4s written by Mark Mascolini - (03/1/11)   Lower CD4 Count Before ART Tied to Higher Risk of Three Non-AIDS Diseases written by Mark Mascolini - (03/1/11)   In Gay Men Over 50, Frailty More Common With HIV Than Without (MACS) written by Mark Mascolini - (03/1/11)   Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, a Potentially First-in-Class Oral HIV Attachment Inhibitor - (03/1/11)